Merck Q3 Results - Q3 Top Pharma Company Earnings Reports

View Merck's Q3 Earnings Report

FiercePharma says: Merck posted better-than-expected profits, aided by a.) strong sales of its diabetes meds and HIV treatments; b.) a one-time $1.7 billion gain on the sale of its animal health business Merial; and c.) cost-cutting, particularly in marketing-and-administrative. Profits came in at $3.42 billion on a 2 percent growth in sales to $6.05 billion. Read more...

Highlights

  • Third-Quarter 2009 Non-GAAP EPS Increases 13 Percent to $0.90, Excluding Certain Items; Reports Third-Quarter GAAP EPS of $1.61, Including Gain from Merial Sale
  • Continued Growth of Key Products, JANUVIA, JANUMET, ISENTRESS and SINGULAIR, Drives Strong Results
  • Merck Updates Full-Year 2009 Non-GAAP EPS Range to $3.20 to $3.30, Excluding Certain Items, and 2009 GAAP EPS Range to $3.69 to $3.89

Check out Merck's current earnings estimates from CNN Money

Merck's Website: http://www.merck.com

Merck Q3 Results - Q3 Top Pharma Company Earnings Reports
Read more on

Suggested Articles

Novartis has touted early success for its new eye drug Beovu, but an alert tying the drug to potential vision loss might cause docs to balk.

Sanofi will unload six manufacturing sites and 3,100 employees into a new API production company as it looks for €2 billion in cost savings.

With a new target date approaching for its competitor to Lantus, the FDA has again given Biocon’s insulin manufacturing plant in Malaysia a once over.